Physician profile
Eric C Baumann
NPI 1538194162
$5,491.26
in general payments reported to CMS, 2019-2025
40 companies · $852 in 2025
The $852 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $765 · 2020: $289 · 2021: $566 · 2022: $791 · 2023: $1,018 · 2024: $1,211 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,069 · Education: $11.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,068.57 |
| Education | $11.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,067.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $847.50 | 2021-2025 | Vraylar |
| Lilly USA, LLC | $763.67 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $331.35 | 2019-2025 | Otezla, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $253.70 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.87 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $217.05 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.34 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $200.98 | 2019-2022 | |
| Pfizer INC. | $172.26 | 2019-2023 | |
| Novo Nordisk INC | $146.14 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $116.15 | 2021-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.56 | 2024-2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $96.94 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $79.29 | 2023-2025 | Cologuard Collection Kit |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Baumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.